No connection

Search Results

MGX vs POCI

MGX
Metagenomi Therapeutics, Inc.
BEARISH
Price
$1.40
Market Cap
$52.7M
Sector
Healthcare
AI Confidence
95%
POCI
Precision Optics Corporation, Inc.
BEARISH
Price
$4.70
Market Cap
$51.4M
Sector
Healthcare
AI Confidence
90%

Valuation

P/E Ratio
MGX
--
POCI
--
Forward P/E
MGX
-0.84
POCI
--
P/B Ratio
MGX
0.33
POCI
3.89
P/S Ratio
MGX
2.09
POCI
2.1
EV/EBITDA
MGX
0.74
POCI
-6.15

Profitability

Gross Margin
MGX
-274.58%
POCI
9.7%
Operating Margin
MGX
-623.04%
POCI
-23.65%
Profit Margin
MGX
0.0%
POCI
-28.33%
ROE
MGX
-44.66%
POCI
-73.56%
ROA
MGX
-21.99%
POCI
-20.83%

Growth

Revenue Growth
MGX
-59.3%
POCI
62.8%
Earnings Growth
MGX
--
POCI
--

Financial Health

Debt/Equity
MGX
0.26
POCI
0.47
Current Ratio
MGX
7.22
POCI
1.05
Quick Ratio
MGX
7.08
POCI
0.58

Dividends

Dividend Yield
MGX
--
POCI
--
Payout Ratio
MGX
0.0%
POCI
0.0%

AI Verdict

MGX BEARISH

MGX exhibits critical financial distress, highlighted by a Piotroski F-Score of 0/9, indicating a total lack of fundamental improvement across all measured categories. The company suffers from a catastrophic negative gross margin (-274.58%) and a significant decline in year-over-year revenue (-59.30%), suggesting a failing or highly inefficient business model. While the current ratio of 7.22 provides a temporary liquidity cushion, the combination of bearish insider selling by the CEO and CFO and a 0/100 technical trend suggests a lack of confidence in near-term recovery. Despite a high analyst target price of $9.33, the deterministic data points to a high-risk speculative asset in a downward spiral.

Strengths
Strong short-term liquidity (Current Ratio: 7.22)
Low leverage (Debt/Equity: 0.26)
Trading significantly below book value (P/B: 0.33)
Risks
Critical fundamental weakness (Piotroski F-Score: 0/9)
Negative gross margins indicating unsustainable cost structure
Severe revenue contraction (-59.30% YoY)
POCI BEARISH

POCI exhibits severe financial distress, highlighted by a critical Piotroski F-Score of 1/9, indicating fundamental weakness across almost all health metrics. While the company shows impressive top-line revenue growth of 62.80%, this growth is not translating into profitability, as evidenced by a -28.33% profit margin and a catastrophic -73.56% ROE. Liquidity is tight with a Quick Ratio of 0.58, and the company has failed to beat earnings estimates in the last four quarters. The recent short-term price rally appears decoupled from the underlying financial deterioration.

Strengths
Strong YoY revenue growth of 62.80%
Strong Q/Q revenue growth of 62.76%
Relatively low Debt/Equity ratio of 0.47
Risks
Critical Piotroski F-Score (1/9) indicating poor financial health
Deeply negative profitability (Profit Margin -28.33%, ROE -73.56%)
Poor liquidity position with a Quick Ratio of 0.58

Compare Another Pair

MGX vs POCI: Head-to-Head Comparison

This page compares Metagenomi Therapeutics, Inc. (MGX) and Precision Optics Corporation, Inc. (POCI) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile